Results 361 to 370 of about 12,182,524 (404)
Some of the next articles are maybe not open access.
Bone-Vascular Axis in Chronic Kidney Disease.
Advances in Chronic Kidney Disease, 2019Patients with chronic kidney disease (CKD) are at increased risk of osteoporosis and vascular calcification. Bone demineralization and vascular mineralization go often hand in hand in CKD, similar to as in the general population.
P. Evenepoel +3 more
semanticscholar +1 more source
2013
Paget’s disease of bone (PDB) affects up to 1% of people of European origin aged 55 years and above. It is characterized by focal abnormalities of bone remodelling which disrupt normal bone architecture, leading to expansion and reduced mechanical strength of affected bones.
openaire +1 more source
Paget’s disease of bone (PDB) affects up to 1% of people of European origin aged 55 years and above. It is characterized by focal abnormalities of bone remodelling which disrupt normal bone architecture, leading to expansion and reduced mechanical strength of affected bones.
openaire +1 more source
The Bioarchaeology of Metabolic Bone Disease
, 2020R. Ives, S. Mays, M. Brickley
semanticscholar +1 more source
Clinical Endocrinology News, 2006 2002
Publisher Summary This chapter focuses on Paget's disease, which is a common disorder of the skeleton that is local in nature and extremely variable in its clinical manifestations. Skeletal deformity and pain are most common symptoms, and deformities are usually most apparent in the skull, face, and lower extremities.
Frederick R. Singer, G. David Roodman
openaire +3 more sources
Publisher Summary This chapter focuses on Paget's disease, which is a common disorder of the skeleton that is local in nature and extremely variable in its clinical manifestations. Skeletal deformity and pain are most common symptoms, and deformities are usually most apparent in the skull, face, and lower extremities.
Frederick R. Singer, G. David Roodman
openaire +3 more sources
Current Treatment Options in Oncology, 2001
The major clinical manifestation of multiple myeloma results from osteolytic bone destruction. The only currently Food and Drug Administration-approved drug for the treatment of the bony complications of multiple myeloma is monthly intravenous pamidronate at a dose of 90 mg infused over 4 hours. Recent studies have shown the safety of 2-hour infusions.
openaire +3 more sources
The major clinical manifestation of multiple myeloma results from osteolytic bone destruction. The only currently Food and Drug Administration-approved drug for the treatment of the bony complications of multiple myeloma is monthly intravenous pamidronate at a dose of 90 mg infused over 4 hours. Recent studies have shown the safety of 2-hour infusions.
openaire +3 more sources
Bone-Targeted Therapies in Cancer-Induced Bone Disease
Calcified Tissue International, 2018S. Sousa, P. Clézardin
semanticscholar +1 more source
Onconephrology: The intersections between the kidney and cancer
Ca-A Cancer Journal for Clinicians, 2021Mitchell H Rosner +2 more
exaly
2011
In 1876, Sir James Paget presented to the Royal Medical and Chirurgical Society of London an account of his experience with a previously unrecognized disease of the skeleton, which he termed osteitis deformans and has since born his name. Paget’s disease of bone is a focal skeletal disorder which progresses slowly and leads to changes in the shape and ...
openaire +1 more source
In 1876, Sir James Paget presented to the Royal Medical and Chirurgical Society of London an account of his experience with a previously unrecognized disease of the skeleton, which he termed osteitis deformans and has since born his name. Paget’s disease of bone is a focal skeletal disorder which progresses slowly and leads to changes in the shape and ...
openaire +1 more source